PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
1 .- 20 . (canceled)
21 . A method of treating H. pylori infection comprising:
orally administering for an effective period of time a pharmaceutical composition in the form of a capsule, each capsule comprising 12.5 mg rifabutin/250 mg amoxicillin mixed minitablets and 10 mg omeprazole minitablets,
wherein release of at least 70% of the omeprazole is delayed from 120 to at least 240 minutes following oral administration.
22 . The method of claim 21 , wherein at least 70% of the rifabutin/amoxicillin is released within 60 minutes following oral administration.
23 . The method of claim 21 , wherein the effective period of time is a time sufficient so as to result in an eradication rate of at least 80%.
24 . The method of claim 21 , comprising administering orally 4 capsules three times daily for a total daily oral dose of 150 mg rifabutin, 3000 mg amoxicillin, and 120 mg omeprazole for 14 days.
25 . The method of claim 21 , wherein the omeprazole is magnesium omeprazole.
26 . The method of claim 21 , wherein the rifabutin is 25-O-desacetylrifabutin.
27 . The method of claim 21 , wherein the rifabutin is 25-O-desacetylrifabutin, the amoxicillin is amoxicillin trihydrate and the omeprazole is magnesium omeprazole.
28 . The method of claim 21 , wherein the amoxicillin is amoxicillin trihydrate.
29 . A method of treating H. pylori infection comprising:
orally administering for an effective period of time a pharmaceutical composition in the form of a capsule comprising:
(1) an immediate release first dosage composition in the form of minitablets, the immediate release first dosage composition comprising rifabutin and amoxicillin; and
(2) a delayed release second dosage composition in the form of enteric coated minitablets, the delayed release second dosage composition comprising a proton pump inhibitor
wherein release of at least 70% of the proton pump inhibitor is delayed from 120 to at least 240 minutes following oral administration.
29 . The method of claim 29 , wherein the proton pump inhibitor is one of omeprazole, pantoprazole, lansoprazole, ilaprazole, dexlansoprazole, esomeprazole and rabeprazole, pharmaceutically acceptable salt and solvates thereof or combinations thereof.
30 . The method of claim 29 , wherein the proton pump inhibitor is magnesium omeprazole.
31 . The method of claim 29 , wherein at least 70% of the rifabutin/amoxicillin is released within 60 minutes following oral administration.
32 . The method of claim 29 , wherein the effective period of time is a time sufficient so as to result in an eradication rate of at least 80%.
33 . The method of claim 29 , wherein the rifabutin is 25-O-desacetylrifabutin.
34 . The method of claim 29 , wherein the amoxicillin is amoxicillin trihydrate.
35 . The method of claim 28 , wherein the rifabutin is 25-O-desacetylrifabutin, the amoxicillin is amoxicillin trihydrate and the proton pump inhibitor is magnesium omeprazole.
36 . The method of claim 28 , comprising administering orally 4 capsules three times daily for a total daily oral dose of 150 mg rifabutin, 3000 mg amoxicillin, and 120 mg omeprazole for 14 days.